Book a Meeting

Fc Engineered Anti-Human CD38 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ17] (CAT#: BioBet-C017ZP) Datasheet

Whole Human Antibody
CDC-enhanced Daratumumab is a Fc-modified anti-CD38 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Daratumumab, the Fc region of Daratumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Multiple Myeloma (MM)
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop CDC-enhanced Daratumumab. For commercial partners interested in our CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
platelet derived growth factor receptor alpha
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
Alternative Names
Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor, Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC; PDGFR-2;
Gene ID
UniProt ID
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Human IgG1
Daratumumab is an anticancer drug that specifically targets CD38. It received accelerated FDA approval in November 2016 for a breakthrough therapeutic drug for multiple myeloma.
Multiple Myeloma (MM)
Not Available

Daratumumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the CD38 antigen. CD38 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. CD38 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Daratumumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to CD38 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.

Multiple Myeloma (MM)

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *